The success of the World Health Organization smallpox eradication program three decades ago resulted in termination of routine vaccination and consequent decline in population immunity. Despite concerns regarding the reintroduction of smallpox, there is little enthusiasm for large-scale redeployment of licensed live vaccinia virus vaccines because of medical contraindications and anticipated serious side effects. Therefore, highly attenuated strains such as modified vaccinia virus Ankara (MVA) are under evaluation in humans and animal models. Previous studies showed that priming and boosting with MVA provided protection for >2 years in a monkeypox virus challenge model. If variola virus were used as a biological weapon, however, the ability of a vaccine to quickly induce immunity would be essential. Here, we demonstrate more rapid immune responses after a single vaccination with MVA compared to the licensed Dryvax vaccine. To determine the kinetics of protection of the two vaccines, macaques were challenged intravenously with monkeypox virus at 4, 6, 10, and 30 days after immunization. At 6 or more days after vaccination with MVA or Dryvax, the monkeys were clinically protected (except for 1 of 16 animals vaccinated with MVA), although viral loads and number of skin lesions were generally higher in the MVA vaccinated group. With only 4 days between immunization and intravenous challenge, however, MVA still protected whereas Dryvax failed. Protection correlated with the more rapid immune response to MVA compared to Dryvax, which may be related to the higher dose of MVA that can be tolerated safely.
S mallpox, one of the most devastating diseases of man, was eradicated three decades ago through an intensive vaccination program spearheaded by the World Health Organization (1) . A byproduct of this success was the cessation of routine vaccination and the consequent decline in population immunity. Although no animal reservoir exists, contingency vaccination plans have been made because of a concern that terrorists might release variola virus (VARV) (2, 3) . The licensed smallpox vaccines consisting of live vaccinia virus (VACV) are highly efficacious, although serious side effects can occur particularly in individuals who are immunocompromised or have a history of eczema (4) . During the recent immunization of potential medical first responders in the United States, the incidence of adverse reactions was lower than in historical records because of careful prescreening, although myocarditis was recognized as a new complication (5) . However, such prescreening of the general population would be difficult in an emergency situation and further would eliminate many individuals and their families with high risk of severe side reactions to the vaccine. Therefore, the development and testing of safer live vaccines such as modified VACV Ankara (MVA) has been mandated. MVA was derived by Ͼ500 passages of the parent virus in chicken embryo fibroblast cells (6) , leading to deletions and mutations that severely restrict the replication and virulence of the vaccine even in immunocompromised hosts (7) (8) (9) (10) (11) (12) . MVA essentially provides a single round ''pseudo live'' immunization because viral assembly and subsequent spread are blocked without impairing gene expression (13) . To compensate for the inability of MVA to spread to other cells, relatively high doses have been used for vaccination (14) . The immune responses to MVA and Dryvax are generally similar, although some differences have been found (15, 16) .
MVA was safely administered to Ϸ120,000 individuals in Germany in the 1970s (6, 17) and to smaller groups in recent clinical trials as a potential smallpox vaccine and in recombinant form as a vaccine for other diseases including HIV and cancer (18) (19) (20) (21) . The efficacy of a MVA smallpox vaccine, however, is uncertain because it was not tested under field conditions before smallpox was eradicated. Consequently, there is a reliance on animal models to evaluate the efficacy of candidate vaccines. Thus far, there has been only limited success in developing a lethal animal model for VARV in monkeys (22) . MVA has been shown to induce rapid, short-term protection in a mouse model using a homologous pathogenic VACV challenge (14, 23, 24) . Monkeypox virus (MPXV), which belongs to the same Orthopoxvirus genus as VARV, causes a disease in humans that is clinically similar to smallpox, although the fatality rate and the spread from person to person are lower (25) . Recent studies have shown that immunization with either MVA or a conventional licensed smallpox vaccine induces humoral and cellular immune responses that protect macaques against lethal infection with MPXV (26, 27) . In those studies, the monkeys received two immunizations with MVA 4-8 weeks apart and were challenged with MPXV after an additional 8-11 weeks. Furthermore, macaques immunized twice with recombinant MVA resisted a MPXV challenge Ͼ2 years after vaccination, demonstrating the durability of protective immunity (28, 29) . However, the ability of a vaccine to rapidly elicit immunity is essential because widespread vaccination is unlikely before verification of smallpox. Historical and anecdotal evidence from the smallpox eradication campaign suggests that the conventional vaccine can confer protection if administered a few days after exposure to variola virus during the 1-2 week incubation prodrome (1, 30) . The present study was designed to determine whether a single dose of MVA could induce rapid protective immunity in the monkeypox model.
Results
Immune Responses to MVA and Dryvax. Macaques were immunized intramuscularly with 1 ϫ 10 8 infectious units of MVA or 2.5 ϫ 10 5 infectious units of Dryvax intradermally. These doses and routes of administration are comparable to those used in clinical smallpox vaccine trials (18, 31, 32) . The temporal development of VACV-specific antibody and CD8 ϩ T cell responses after immunizations are shown in Fig. 1 . Antibodies were first detected by ELISA on days 7 and 10 for MVA and Dryvax, respectively ( Fig. 1 A) . The difference between the two groups was statistically significant (P ϭ 0.0286 on days 7 and 10, Mann-Whitney test) and was consistent with our previous data (26) . By day 17, however, the titers plateaued to equivalent levels. Similarly, neutralizing antibody to VACV, measured by using a quantitative fluorescent reporter gene infectivity assay (33) , was detected earlier in the MVA group (day 7) than in the Dryvax group (day 10), although by day 17 the antibody levels in the Dryvax group surpassed those in the MVA group (Fig. 1B) . VACV-specific CD8 ϩ T cell responses were measured by immunostaining fresh peripheral blood mononuclear cells. CD8 ϩ / INF-␥ ϩ responses were detected in all animals with peaks on days 7 and 10 for the MVA and Dryvax groups, respectively (Fig.  1C) . Although the average peak values were higher in the Dryvax than in the MVA group, the difference was not statistically significant.
We also investigated systemic changes in the levels of INF-␥, ⌻⌵F-␣, IL-2, IL-4, IL-5 and IL-10 from 2 to 27 days after Dryvax and MVA. The IFN-␥ response was dominant, similar to the findings in healthy human adults that had received Dryvax (34) . The timing and magnitude of the IFN-␥ response was variable, with one monkey in each vaccine group showing an increase over base-line on days 4-10, two in each group showing an increase between days 7 and 10 and one in each group having no increase. There was no significant elevation of IFN-␥ in the two unvaccinated animals.
In summary, a single injection of MVA induced more rapid antibody and CD8 ϩ /INF-␥ ϩ responses than Dryvax, whereas the magnitudes of the responses were similar or slightly lower. The more rapid immune responses to MVA compared with Dryvax could be explained by the higher inoculum dose of the former. Whereas, the nonreplicating MVA was given as a bolus of 1 ϫ 10 8 infectious units, only 2.5 ϫ 10 5 infectious units of Dryvax were administered. The delay for Dryvax probably reflects the time needed to increase the immunogen mass by replication. Although theoretically the dose of Dryvax could be increased, that would be unlikely in view of the troublesome side effects accompanying the existing protocol.
Protection Against MPXV Challenge. For protection studies, 50 cynomolgous macaques were divided into five groups of 10 animals. Each group was subdivided as follows: Four animals were immunized with Dryvax, four received MVA, one received saline intradermally, and one received saline intramuscularly. Groups were challenged intravenously with 5 ϫ 10 7 plaque forming units (pfu) (Ϸ10 LD 50 ) of MPXV at 30 or 10 days after vaccination or with 5 ϫ 10 6 pfu (Ϸ1 LD 50 ) at 10, 6, or 4 days after vaccination. The i.v. route of challenge, which mimics the systemic phase of smallpox (35) , has been used previously and demonstrates reproducible disease endpoints (26, 36) . After challenge with 5 ϫ 10 7 pfu, all controls experienced severe disease requiring euthanasia between days 5 and 7. After challenge, the viral genome load in the blood of control animals (henceforth referred to as viremia) increased between days 5 and 7 reaching titers of 2 ϫ 10 7 to 1.4 ϫ 10 8 (mean 5.3 ϫ 10 7 ) (Fig.  2A) ; total body skin lesion counts were in excess of 2,500 ( Table  1 ). The first group of vaccinated animals was challenged with 5 ϫ 10 7 pfu of MPXV on day 30, a time at which the antibody response had reached a plateau and CD8 ϩ T cells had declined. These animals all survived the 32-day follow-up period (Fig. 2 A) . Viremia in the Dryvax-immunized animals dropped to base line levels in 3 days and none developed skin lesions ( Fig. 2 A and Table 1 ). Three of the four MVA-immunized animals displayed a transient viremia, reaching an average level 2 logs lower than in the controls before declining to baseline (Fig. 2 A) . In the fourth MVA-immunized animal, viremia dropped to base line in 3 days. The MVA-immunized animals had no clinical symptoms except for skin lesions that resolved by day 9 (Table 1) . Next, we determined the outcome when the challenge with 5 ϫ 10 7 pfu of MPXV occurred only 10 days after vaccination. The result was similar to the 30-day challenge ( Fig. 2B and Table 1 ) except that two of the Dryvax-immunized animals developed a small number of skin lesions and one exhibited a low viremia. For individual MVA-and Dryvax-immunized monkeys, there was a good correlation between the levels of viremia and numbers of skin lesions (Table 1) . Thus, a single inoculation with MVA provided substantial protection to the severe MPXV challenge given 10 or 30 days later but was inferior to Dryvax based on virus load and skin lesions. Because the challenge dose of 5 ϫ 10 7 pfu of MPXV induced severe disease and death within only 5 to 7 days in unvaccinated animals, the dose was lowered to 5 ϫ 10 6 pfu for further studies. Under these conditions, viremia in unimmunized animals increased between days 6 and 9, reaching peak values of 2.1 ϫ 10 6 to 1.4 ϫ 10 8 (mean of 4.1 ϫ 10 7 ) and large numbers of skin lesions developed ( Fig. 2 C and Table 1 ). Four of these animals were killed because of severe disease and two recovered after 18 days. A challenge at 10 days after vaccination was repeated under the new conditions. The Dryvax group was completely protected, with no viremia or skin lesions (Fig. 2 C and Table 1 ). Only two monkeys in the MVA group exhibited viremia (7.8 ϫ 10 4 and 7 ϫ 10 5 ); three had relatively low numbers of skin lesions and one had none ( Fig. 2 C and Table 1 ). When the time between vaccination and challenge was decreased to 6 days, the protection achieved with Dryvax and MVA was comparable. In each group, a rise in MXPV genome loads was detected in two of four animals and all developed skin lesions (Fig. 2 D and Table 1 ). In addition, one monkey in the MVA group was killed on day 9 after challenge. Although that animal had a high lesion count of 625, the viral load was much lower than of unvaccinated animals. When the period between immunization and challenge was shortened to 4 days, a striking difference was observed between the Dryvax and MVA groups. The viremia was controlled by the MVA group but not by the Dryvax group. Indeed, viremia, lesion counts, and survival in the Dryvax group were indistinguishable from that of the unimmunized controls ( Fig. 2 E and Table 1 ). Three of the four monkeys in the Dryvax group were killed because of severe disease by days 10-14. In contrast, in the MVA group, disease was transient (peak viral loads were 27-and 37-fold lower than unimmunized and Dryvax groups, respectively) and all of the animals survived.
The immune responses shown in Fig. 1 were from the monkeys that had been immunized 30 days before challenge. Based on those data, we considered that the immune response of animals vaccinated with MVA at 4 days before challenge would have occurred early enough to modulate the infection. To confirm this, we compared the kinetics of antibody induction with viremia and clinical signs. No antibody to VACV was detected on the day of challenge or 3 days later (4-6 days after immunization) (Fig. 3) . However, by day 6 after challenge (day 10 after immunization), antibody titers were Ͼ10-fold higher in the MVA group compared to Dryvax (P ϭ 0.0286, Mann-Whitney test). These values represented vaccine-induced responses because naïve controls were still negative on day 6 (Fig. 3) . By 9 days after challenge (day 14 after immunization), the naïve animals had made a strong antibody response and the antibody levels of the Dryvax group had caught up to MVA (Fig. 3) . In the MVA vaccinated animals, the viremia was cleared and the pox lesions healed by 9 days after challenge, 3 days after the antibody response was detected ( Fig. 2 and Table 1 ). Although the naïve and Dryvax groups had made antibody by day 9 after challenge, they were unable to clear the virus and succumbed within a few days ( Fig. 2 and Table 1 ). Because of the biological containment level, we were unable to remove live cells to determine T cell responses after MPXV challenge. However, based on the timing in Fig. 1B , we can predict that the MVA-induced CD8 ϩ response could also have contributed to the clinical outcome.
Discussion
Conventional smallpox vaccines, such as Dryvax, induce immune responses that offer rapid and long-lasting protection after a single dose (1) . Previous studies had shown that two immunizations with MVA could provide protection for Ͼ2 years in a non-human primate monkeypox model (28, 29) . However, because the second immunization with MVA gave a substantial boost in antibody response in monkeys, the efficacy of a single MVA vaccination could not be predicted. The purpose of the present study was to determine whether a single MVA vaccination would protect and to assess the time required for develop- ment of immunity. Previous studies had shown that smallpox vaccine-induced antibodies are necessary and sufficient for protection in the monkeypox model (36) .
The present studies were carried out by using two challenge doses of MPXV administered intravenously. With the high dose of 5 ϫ 10 7 pfu (Ϸ10 LD 50 ), skin lesions on naïve animals developed in 5-6 days and all had to be killed. At the more moderate dose of 5 ϫ 10 6 pfu (Ϸ1 LD 50 ), the skin lesions appeared on day 6 coincident with viremia but resolved in 4 of 6 control animals. To estimate the times required to develop protective immunity, monkeys were challenged 4, 6, 10 or 30 days after vaccination. The degree of protection was determined by counting skin lesions and measuring viremia, as well as by clinical observations. There was a good correlation between the lesion number and viremia (Table 1) . Using Dryvax as the standard, we found that complete protection against the high dose occurred when the animals were challenged at thirty days after vaccination, as judged by absence of viremia or skin lesions. With a dose of 5 ϫ 10 6 pfu, complete protection was achieved when the animals were challenged at 10 days after Dryvax. After a day 6 challenge, viremia was detected and all monkeys developed skin lesions although all survived. However, when the monkeys were challenged at 4 days after Dryvax, only one of four animals survived compared with four of six controls, and viremia and skin lesions were similar to the controls. The picture was somewhat different with MVA. On the one hand, the animals all survived when challenged only 4 days after vaccination and only a single animal in the entire study became seriously ill and had to be killed. Furthermore, the viremia and skin lesions were greatly reduced compared with controls regardless of the challenge dose or the time interval after MVA vaccination. Nevertheless, complete protection as judged by the absence of skin lesions was rare.
The MVA and Dryvax immunizations differed with regard to dose (1 ϫ 10 8 pfu versus 2.5 ϫ 10 5 pfu, respectively) and route of administration (intramuscular versus skin scarification, respectively). Previous studies with mice demonstrated that the 400-fold greater amount of MVA compared to Dryvax was necessary to achieve comparable antibody levels after a single injection (14) . MVA resembles an inactivated vaccine with regard to the relatively large inoculum and replication deficiency but mimics a live virus with regard to intracellular protein synthesis and induction of a CD8 ϩ T cell response. Because of the low inoculum, a week is necessary for Dryvax to replicate and produce a substantial immunogenic mass as judged by the formation of a skin lesion. Presumably for this reason, antibody and T cell responses occurred more rapidly after MVA than Dryvax, as previously observed (26) . The timing of the antibody and T cell responses correlated with the rapid acquisition of protective immunity after MVA. Stimulation of innate immune responses may also contribute to protection at short times after vaccination. In this regard, MVA has been shown to induce higher NF-kB responses in cultured cells than a replicating strain of VACV (37, 38) . However, we detected a similar systemic elevation of IFN-␥ in the monkeys vaccinated with MVA and Dryvax.
The finding that a single inoculation of MVA induces rapid protection in the monkeypox model suggests that it might be used effectively to vaccinate unimmunized individuals in an emergency situation caused by a sudden outbreak of smallpox. Analysis of historical records suggests that primary vaccination within 4 days after exposure to smallpox is usually protective of serious illness (30) . Because the incubation period preceding systemic smallpox is Ϸ2 weeks (35) , it is understandable that Dryvax administered only 4 days before an i.v. challenge would not be protective. The more rapid immune responses of monkeys to MVA compared to Dryvax suggest that the window of opportunity for protective vaccination might be extended by several days. Further comparisons of the MPXV model with human smallpox are difficult in view of the differences between the viruses, host animals, routes of infection, and time to develop disease (35) . The emphasis of this study was to determine whether a single vaccination could provide rapid protection but the duration beyond 30 days was not investigated. However, a second dose has been shown to boost antibody responses to levels equal to that of Dryvax (26, 27) and to provide protection against MPXV for Ͼ2 years (28, 39) .
Materials and Methods
Virus Preparation. MVA 1974/NIH clone 1 (14) was propagated in chicken embryo fibroblast cells and purified by sedimentation through a sucrose cushion. Dryvax (Wyeth Laboratories, Inc.) was obtained from the U.S. Centers for Disease Control and Prevention, diluted and stored as recommended. MPXV strain Zaire-79 was obtained from the National Institutes of Health Biodefense and Emerging Infections Research Resources Repository.
VACV ELISA. Microtiter plates were coated with 10 6 pfu per well of sucrose gradient purified VACV strain WR and fixed with paraformaldehyde. Two-fold serial dilutions of heat inactivated sera were added, followed by horseradish peroxidase conjugated anti-monkey IgG-POD (Accurate Chemical and Scientific Corp.) and BM blue substrate (Roche Molecular Biochemicals).
VACV Neutralization Assay.
A VACV neutralization assay based on flow cytometric detection of green fluorescent protein was used (33) . Two-fold serial dilutions of sera were incubated with VV-NP-S-EGFP for 1 h at 37°C. HeLa S3 cells were added and incubated overnight in the presence of cytosine arabinoside. Fluorescent cells were enumerated with a FACScalibur flow cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star, Inc. ). IC 50 values were determined with PRISM software (Graph Pad).
Intracellular Cytokine Staining.
Fresh peripheral blood mononuclear cells were infected overnight with VACV (10 pfu per cell) in the presence of Brefeldin A then stained with antibodies to CD3, CD8, and IFN-␥ conjugated to phycoerythrin, fluorescein isothyocyanate, and allophycocyanin (BD PharMingen), respectively. Cells were enumerated with a FACScaliber flow cytometer and analyzed with FlowJo software. Viral Genome Load. Quantitative TaqMan 3Ј-Minor Groove binder PCR was used to determine the number of MPXV genomes in the blood as previously described (40) .
Serum Cytokine Measurements. Cytokines INF-␥, TNF-␣, IL-2, IL-4, IL-5, and IL-10 were measured in sera taken before vaccination and on days 2, 4, 7, 10, 17, and 27 after vaccination by using a Bio-Plex system (Bio-Rad Laboratories) according to the manufacturer's protocol. 
